Recently, McLean hospital conducted a 4 month taurine study which showed a reduction in mania
ratings. As a follow-up to the preliminary taurine study, and complementary to the currently
ongoing double-blind, placebo-controlled trial for taurine in adults with bipolar disorder,
this study will target adolescent bipolar subjects (type I) with symptoms of mania or mixed
mania. To our knowledge, this would be the first study to evaluate the effects of the novel
compound taurine in adolescent subjects with bipolar disorder.
We hypothesize there will be a positive response in some adolescents from taurine treatment,
and this positive response will be greater than that expected by chance. This study may
demonstrate that taurine is a well-tolerated and effective adjunct treatment for mania in
bipolar disorder.
Phase:
Phase 1
Details
Lead Sponsor:
Cambridge Health Alliance
Collaborators:
Mclean Hospital Stanley Medical Research Institute